Memorial Sloan Kettering Cancer Center
Participants will receive retifanlimab during 28-day treatment Cycles and will continue to receive retifanlimab for up to 6 Cycles (up to 12 Cycles with study doctor approval) unless the participant's cancer comes back, have serious side effects and cannot continue study treatment, or the study doctor thinks it is in the participant's best interest to stop.
Inclusion Criteria: * Subject or legally authorized representative is willing and able to provide written informed consent. * Age ≥ 18 on day of signing informed consent. * Consent for use of archival tissue and blood draws for research purposes. * Documentation of Disease o Patients must have pathologically confirmed anal squamous cell carcinoma. ° Pathology confirmation of the primary tumor at time of initial diagnosis is acceptable. * Disease Specific Criteria * Patients must have MRD after completion of definitive-CRT defined as: * Detectable on the last day of or after comp…
IV Retifanlimab every 4 weeks for 6 cycles